Health
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
UCB, a global biopharmaceutical company, today announced it will present 26 abstracts from its epilepsy portfolio at the International Epilepsy Congress (IEC) Congress, Lisbon, Portugal, August 30 – September 3, 2025. Data will focus on developmental and epileptic encephalopathies (DEEs), such as Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), as well as prolonged seizures, seizure emergencies and early pipeline research.
About this update from Ucb S.a.
[{"type":"list","items":[{"val":[{"type":"text","content":"26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies","length":155,"tagName":"p"}]},{"val":[{"type":"text","content":"Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome[2]","length":203,"tagName":"p"}]},{"val":[{"type":"text","content":"Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors[3],[4]","length":286,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers[5],[6],[7]","length":113,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":757,"olType":false},{"type":"text","content":"BRUSSELS, Aug. 29, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced it will present 26 abstracts from its epilepsy portfolio at the International Epilepsy Congress (IEC) Congress, Lisbon, Portugal, August 30 – September 3, 2025. Data will focus on developmental and epileptic encephalopathies (DEEs), such as Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), as well as prolonged seizures, seizure emergencies and early pipeline research.","length":473,"tagName":"p"},{"type":"text","content":"Dimitrios Bourikas, Global Medical Head of DEE and Epilepsy, UCB, commented: "At UCB, we are committed to driving improvements in all aspects of care for people living with epilepsies and severe epileptic conditions. The breadth of data we are presenting at the International Epilepsy Congress reflects our dedication to advancing innovative solutions that address real-world patient needs. By deepening insights into disease mechanisms, treatment outcomes, and the experiences of both patients and caregivers, we strive to shape a better future for those affected by epileptic conditions."","length":600,"tagName":"p"},{"type":"text","content":"Highlights of data to be presented at IEC:","length":42,"tagName":"p"},{"ty...